Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
Date:3/10/2012

ations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our history of losses and expectation of incurring continued losses; the risk that our stockholders may not approve our recent financing transaction and our ability to repay the indebtedness incurred in connection with issuance and sale of the convertible notes if such notes are not converted into shares of common stock; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our  proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); and our ability to comp
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
(Date:7/10/2014)... basis of psychiatric disorders has been extremely challenging because ... but are insufficient to cause disease. Now investigators reporting ... journal Cell Stem Cell describe a strategy ... interact with other risk factors or environmental exposures to ... pinpoints a genetic variant that may predispose individuals to ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Medivation, Inc.,(Nasdaq: MDVN ) today announced the ... regulatory and quality, Mohammad Hirmand, M.D., to vice,president, ... translational medicine., "As we enter Phase 3 ... the team to lead and advance our clinical ...
... Biosciences, Inc. (Nasdaq: MGRM ) today announced ... of Vice President, Research and,Development, Oncology. Dr. Parry ... programs, including the further,development of Monogram,s proprietary VeraTag(TM) ... platform - the HERMark(TM) Breast Cancer,Assay., Dr. ...
... with Canadian Division of Global Pharmaceutical,Company, ... BASKING RIDGE, N.J., March 24 /PRNewswire/ ... Millennium Biotechnologies Group, Inc.,(OTCBB: MBTG) announced today ... distribution agreement for Resurgex(R), its nutritional formula,for ...
Cached Biology Technology:Medivation Announces Senior Management Promotions 2Medivation Announces Senior Management Promotions 3Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 2Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 3Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 4Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals 2Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals 3
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... When battling an epidemic of a deadly parasite, less resistance ... A freshwater zooplankton species known as ... parasite that can infect more than 60 percent of the ... evolves quickly, balancing infection resistance and reproduction. A new ...
... 2012. Metformin, a drug widely used to treat Type II ... the University of Maryland Marlene and Stewart Greenebaum Cancer Center ... Research . Primary liver cancer, or hepatocellular carcinoma, is an ... and is the fastest-growing cause of cancer-related deaths among American ...
... March 30, 2012 The Phoenix Community Alliance (PCA) ... Genomics Research Institute (TGen), with its most prestigious award. ... City Starr Award for his work in improving the ... studying diseases such as Alzheimer,s, diabetes and many types ...
Cached Biology News:Weakness can be an advantage in surviving deadly parasites, a new study shows 2Weakness can be an advantage in surviving deadly parasites, a new study shows 3Commonly used diabetes drug may help to prevent primary liver cancer 2Commonly used diabetes drug may help to prevent primary liver cancer 3Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
... The Bio-Plex maintenance, calibration, and ... custom 96-well plate used for ... calibration procedures using the Bio-Plex ... plate is for use with ...
... sequencing of plasmids and PCR amplicons. ... high performance sequencing pipeline which processes ... day. The key benefits we offer ... rapid turnaround, high sequencing pass rates ...
GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....
Biology Products: